局部万古霉素能否预防髋膝关节置换术后假体周围感染?系统综述
该系统综述检索Embase、MEDLINE和PubMed截至2020年6月,纳入9项研究共3371例接受局部万古霉素的原发髋/膝关节置换患者与2884例未接受者。仅1项研究显示假体周围感染风险降低,8项未显示;6项可比较总体并发症的研究未发现差异,但安全性终点证据不足。结论为不推荐常规使用局部万古霉素。
要点
- 9项研究中仅1项显示局部万古霉素降低原发髋/膝关节置换后假体周围感染风险。
- 6项研究比较总体并发症未见差异,但安全性终点证据不足。
- 不推荐在常规原发全髋或全膝关节置换中预防性使用局部万古霉素。
核心结论
- 缺乏明确疗效证据且安全性终点证据不足,局部万古霉素不应常规用于原发全髋和全膝关节置换。
研究设计与样本
- 遵循PRISMA指南检索Embase、MEDLINE和PubMed截至2020年6月,筛选2408项研究后纳入9项比较局部万古霉素联合标准预防与仅标准预防的研究。
- 纳入18岁以上、随访至少3个月的原发髋/膝关节置换患者,局部万古霉素组3371例,对照组2884例,采用Newcastle-Ottawa量表评估质量为中至高等。
主要发现
- 9项研究中1项发现原发全髋或全膝关节置换后假体周围感染风险降低,8项未发现,9项研究的比值比范围为0.09至1.97。
- 6项可比较总体并发症的研究中,局部万古霉素组与对照组总体并发症风险无差异,6项研究的比值比范围为0.48至0.94。
临床怎么用
- 不建议在常规原发全髋和全膝关节置换中预防性使用局部万古霉素。
- 需等待足够效能的多中心前瞻性试验证实感染风险降低及大型注册数据库安全性审计结果后再考虑推广。
局限性
- 纳入研究对万古霉素相关不常见并发症(如过敏、耳毒性、肾毒性)的检测效能不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Periprosthetic joint infection (PJI) after hip and knee arthroplasty is a leading cause of revision surgery, inferior function, complications, and death. The administration of topical, intrawound vancomycin (vancomycin powder) has appeared promising in some studies, but others have found it ineffective in reducing infection risk; for that reason, a high-quality systematic review of the best-available evidence is needed. QUESTIONS/PURPOSES: In this systematic review, we asked: (1) Does topical vancomycin (vancomycin powder) reduce PJI risk in hip and knee arthroplasty? (2) Does topical vancomycin lead to an increased risk of complications after hip and knee arthroplasty? METHODS: A search of Embase, MEDLINE, and PubMed databases as of June 2020 was performed according to Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. Studies comparing topical vancomycin in addition to standard infection prevention regimens (such as routine perioperative intravenous antibiotics) with standard regimens only in primary hip and knee arthroplasty were identified. Patients 18 years or older with a minimum follow-up of 3 months were included. No restrictions on maximal loss to follow-up or PJI definition were imposed. Studies were excluded if they included patients with a history of septic arthritis, used an antibiotic other than vancomycin or a different route of administration for the intervention, performed additional interventions that differed between groups, or omitted a control group. A total of 2408 studies were screened, resulting in nine eligible studies reviewing 3371 patients who received topical vancomycin (vancomycin powder) during a primary THA or TKA and 2884 patients who did not receive it. Groups were comparable with respect to duration of follow-up and loss to follow-up when reported. Study quality was assessed using the Newcastle-Ottawa scale, showing moderate-to-high quality for the included studies. The risks of PJI and overall complications in the topical vancomycin group were compared with those in the control group. RESULTS: One of nine studies found a lower risk of PJI after primary THA or TKA, while eight did not, with odds ratios that broadly bracketed the line of no difference (range of odds ratios across the nine studies 0.09 to 1.97). In the six studies where overall complications could be compared between topical vancomycin and control groups in primary THA or TKA, there was no difference in overall complication risks with vancomycin (range of ORs across the six studies 0.48 to 0.94); however, we caution that these studies were underpowered to detect differences in the types of uncommon complications associated with vancomycin use (such as allergy, ototoxicity, and nephrotoxicity). CONCLUSION: In the absence of clear evidence of efficacy, and without a sufficiently large evidence base reporting on safety-related endpoints, topical vancomycin (vancomycin powder) should not be used in routine primary THA and TKA. Adequately powered, multicenter, prospective trials demonstrating clear reductions in infection risk and large registry-driven audits of safety-related endpoints are required before the widespread use of topical vancomycin can be recommended. LEVEL OF EVIDENCE: Level III, therapeutic study.
引用
- Wong MT, Sridharan SS, Davison EM, et al. Can Topical Vancomycin Prevent Periprosthetic Joint Infection in Hip and Knee Arthroplasty? A Systematic Review. Clin Orthop Relat Res. 2021. PMID: 33929342. doi:10.1097/CORR.0000000000001777
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。